Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/7/?d=1Neue Studien: Europe PMCdeDisentangling Nicotine vs Non-Nicotine Components of Tobacco Exposure in Psoriasis and Psoriatic Arthritis: A Multivariable and Trans-Ethnic Mendelian Randomization Study.https://www.psoriasis-news.de/articles.html/1_articles/disentangling-nicotine-vs-non-nicotine-components-of-tobacco-exposure-in-psoriasis-and-psoriatic-arthritis-a-multivariable-and-trans-ethnic-mendelian-randomization-study-r536/ObjectiveTo disentangle tobacco constituents in psoriasis, we contrasted nicotine exposure-proxied by the nicotine metabolite ratio (NMR)-with smoking intensity (cigarettes per day, CPD) and evaluated cross-ancestry effects.

Methods

This study applied multivariable Mendelian randomization (MR) jointly modeling genetically proxied NMR (instrumented using variants from a European-ancestry GWAS) and CPD to estimate their independent effects on liability to psoriasis and psoriatic arthritis (PsA). Chronic obstructive pulmonary disease (COPD) served as a positive control. Cross-ancestry generalizability was tested using a trans-ethnic MR (TEMR) framework under conditional likelihood with Nelder-Mead optimization. Sensitivity analyses assessed pleiotropy, heterogeneity, directionality (Steiger), MRLap, RadialMR, and multiple testing (Benjamini-Hochberg).

Results

NMR showed an independent association with higher PsA risk irrespective of CPD (OR = 1.104, 95% CI: 1.039-1.174). CPD retained an independent effect on overall psoriasis after conditioning on NMR (OR = 1.305, 95% CI: 1.082-1.573), while the NMR effect on psoriasis attenuated (P > 0.05). In univariable MR, genetically predicted NMR increased psoriasis risk in Europeans (EUR; OR = 1.032, 95% CI: 1.013-1.051). CPD associated with psoriasis in EUR (OR = 1.130, 95% CI: 1.031-1.239) and strongly in Hispanics (HIS; OR = 1.448, 95% CI: 1.434-1.463), with suggestive evidence in East Asians. Reverse-direction MR indicated psoriasis liability correlated with lower CPD across EUR, EAS, AFR, and HIS (β < 0, Padj < 0.05).

Conclusion

This study supports ancestry-specific differences and suggests distinct roles of nicotine-related versus non-nicotine tobacco smoke constituents in psoriasis and its subtypes, while the underlying biological mechanisms remain to be clarified.

Weiterlesen

]]>536Mon, 30 Mar 2026 08:02:12 +0000A Study on Lifestyle and Dietary Factors in Psoriasis: Global Prevalence Trends in Working-Age Populations, Association with LE4 Lifestyle Factors, and Mendelian Randomization Analysis of Dietary Causal Effects.https://www.psoriasis-news.de/articles.html/1_articles/a-study-on-lifestyle-and-dietary-factors-in-psoriasis-global-prevalence-trends-in-working-age-populations-association-with-le4-lifestyle-factors-and-mendelian-randomization-analysis-of-dietary-causal-effects-r535/BackgroundPsoriasis is a chronic immune-mediated skin disease influenced by genetic, environmental, and lifestyle factors, with increasing burden among working-age adults.

Objective

To examine global trends in psoriasis prevalence among working-age adults, evaluate associations with lifestyle factors using a simplified Life's Essential 4 (LE4) index, and explore potential dietary causal relationships through Mendelian randomization (MR).

Methods

Global prevalence trends from 1990 to 2021 were analyzed using GBD 2021 data, calculating age-standardized rates (ASR) and estimated annual percentage changes (EAPC), with projections to 2031. Regional variations across SDI levels were also assessed. The LE4 index, derived from core lifestyle components of the Life's Essential 8 framework using NHANES data, was evaluated via survey-weighted logistic regression and restricted cubic spline analysis. Two-sample MR analyses were conducted using the inverse-variance weighted (IVW) method to assess dietary traits.

Results

The global prevalence of psoriasis among working-age adults increased from 555.7 to 600.6 per 100,000 (EAPC: 0.22%), with projections reaching 631.6 by 2031; Notably, upward trends were consistently observed across all SDI regions. Higher LE4 scores (≥81.2) were associated with lower odds of psoriasis (OR: 0.518, P=0.040). MR analyses suggested that genetically predicted fizzy drink consumption increased risk (OR: 1.57, P=0.0215), whereas salad vegetable intake showed a protective association (OR: 0.85, P=0.0224).

Conclusion

The burden of psoriasis among working-age adults shows a modest global increase with regional heterogeneity. Healthier lifestyle patterns and favorable dietary factors were associated with reduced risk, highlighting the importance of modifiable behaviors in prevention strategies.

Weiterlesen

]]>535Mon, 30 Mar 2026 08:02:12 +0000Sensitive skin in patients with inflammatory chronic cutaneous disorders: results from an observational study on psoriasis, atopic dermatitis and hand eczema.https://www.psoriasis-news.de/articles.html/1_articles/sensitive-skin-in-patients-with-inflammatory-chronic-cutaneous-disorders-results-from-an-observational-study-on-psoriasis-atopic-dermatitis-and-hand-eczema-r534/BackgroundData on the prevalence of sensitive skin in patients with chronic inflammatory skin diseases are lacking. The aim of this study was to address this gap.

Methods

This observational study included patients with psoriasis, atopic dermatitis or chronic hand eczema who attended the Unit of Dermatology of Ferrara and Messina, Italy, between June and December 2023. All participants completed a 10-item questionnaire for the diagnosis of sensitive skin (score range: 0-10). Participants were classified as having sensitive skin if they scored ≥4.

Results

A total of 188 subjects were included, of whom 82 had psoriasis (mean Psoriasis Area and Severity Index [PASI] 4.2±5.1), 59 had atopic dermatitis (Eczema Area and Severity Index [EASI] 3.5±6.7) and 47 had hand eczema (Hand Eczema Severity Index [HECSI] 39.3±3.26). The mean questionnaire scores were 2.6±2.4 for psoriasis, 4.7±2.9 for atopic dermatitis, and 3.0±2.1 for hand eczema, with significant differences observed between atopic dermatitis and both psoriasis (P<0.001) and hand eczema (P<0.001). The prevalence of sensitive skin was higher among atopic dermatitis patients compared to those with psoriasis (P<0.001) and hand eczema (P<0.01).

Conclusions

In the present study, which should be regarded as a pilot due to the relatively small number of cases included, sensitive skin was both more prevalent and more severe in patients with atopic dermatitis compared to those with psoriasis and hand eczema. Atopic dermatitis appears to promote skin sensitivity, independently of its clinical severity.

Weiterlesen

]]>534Mon, 30 Mar 2026 08:02:12 +0000IL-17A Inhibitors Therapy Affect Oral Fungal and Bacterial Microbiome in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/il-17a-inhibitors-therapy-affect-oral-fungal-and-bacterial-microbiome-in-psoriasis-r533/Weiterlesen

]]>533Mon, 30 Mar 2026 08:02:12 +0000Spatial transcriptomic profiling reveals body site-specific inflammatory differences in psoriasis lesionshttps://www.psoriasis-news.de/articles.html/1_articles/spatial-transcriptomic-profiling-reveals-body-site-specific-inflammatory-differences-in-psoriasis-lesions-r532/No abstract supplied.

Weiterlesen

]]>532Mon, 30 Mar 2026 08:02:12 +0000Machine learning meets psoriasis: identifying key lactylation biomarkers as potential targets for diagnosis and therapieshttps://www.psoriasis-news.de/articles.html/1_articles/machine-learning-meets-psoriasis-identifying-key-lactylation-biomarkers-as-potential-targets-for-diagnosis-and-therapies-r531/No abstract supplied.

Weiterlesen

]]>531Mon, 30 Mar 2026 08:02:12 +0000Long-term safety and efficacy in paediatric psoriasis: Remaining challenges.https://www.psoriasis-news.de/articles.html/1_articles/long-term-safety-and-efficacy-in-paediatric-psoriasis-remaining-challenges-r530/No abstract supplied.

Weiterlesen

]]>530Mon, 30 Mar 2026 08:02:12 +0000Paediatric psoriasis and biologics: An evidence gap in plain sight.https://www.psoriasis-news.de/articles.html/1_articles/paediatric-psoriasis-and-biologics-an-evidence-gap-in-plain-sight-r529/No abstract supplied.

Weiterlesen

]]>529Mon, 30 Mar 2026 08:02:12 +0000Development of transdermal nanofilm containing fluticasone propionate: In-vitro, in-vivo correlation.https://www.psoriasis-news.de/articles.html/1_articles/development-of-transdermal-nanofilm-containing-fluticasone-propionate-in-vitro-in-vivo-correlation-r528/BackgroundPsoriasis is one of the chronic inflammatory skin conditions, affecting about 2-3% of the world population. Steroidal treatment are only best choice of treatments, but it is often associated with side effects due to higher lipophilicity.

Objectives

In this work, a nanoparticle-loaded transdermal film was developed to maintain nanoparticle integrity in the skin.

Methods

Fluticasone propionate loaded chitosan nanoparticles (NPs) were developed, and their particle size, zeta potential, drug loading, entrapment efficiency and scanning electron microscope (SEM) images were determined. The NPs-loaded film was further characterized for appearance, thickness and Fourier Transform Infrared (FTIR) spectra, and an in vitro and in vivo permeation study was conducted.

Results

The particle size of FSNPs was found to be 250nm with +32.4 ±1.5 mV zeta potential, great entrapment efficiency and spherical in shape. In vivo dermato-kinetic studies showed long-term, confined drug release from the NP-formulated film in the epidermal layers, compared with the film containing free drug.

Conclusion

The study demonstrated that the FSNPs-loaded film showed higher skin permeation, which is effective for managing psoriasis and warrants further evaluation.

Weiterlesen

]]>528Mon, 30 Mar 2026 08:02:12 +0000Hibiscetin-Loaded Nanogel Ameliorated the Severity of IMQ-Induced Psoriasis-Like Inflammation in Mice via Down-Regulating Interleukins/TNF-α/NF-κB.https://www.psoriasis-news.de/articles.html/1_articles/hibiscetin-loaded-nanogel-ameliorated-the-severity-of-imq-induced-psoriasis-like-inflammation-in-mice-via-down-regulating-interleukinstnf-%CE%B1nf-%CE%BAb-r527/IntroductionThe rising incidence of inflammatory skin diseases, including psoriasis, has necessitated new treatment approaches. This paper focuses on the development of a hibiscetin-impregnated nanogel that reduces the severity of skin inflammation.

Methods

Imiquimod (IMQ) was used to induce psoriasis-like inflammation in animal models, and the nanogel's worthiness was compared. Nanogel was prepared in different concentrations of hibiscetin, namely F1 (1) and F2 (2), and characterized in terms of appearance, size, charge, spreadability, pH, release kinetics of the drug, skin penetration and stability.

Results

Lab analyses showed that the nanogel possessed desirable characteristics, with an average particle size of 205 nm, a polydispersity index (PDI) of 0.385, and a surface charge of -69.5 mV. Its morphology was confirmed to be spherical by scanning electron microscopy (SEM). The nanogel demonstrated powerful anti-inflammatory properties, including the disappearance of redness and skin thickening, reduced pro-inflammatory cytokine concentrations, reduced oxidative stress markers, and apoptosis-mediated cell death in vivo. Hibiscetin, as an effect of IMQ, also had a reparative effect on damaged skin as evidenced by histopathological studies.

Conclusion

The results imply that hibiscetin-conjugated nanogels offer an option for improving the delivery and therapeutic efficacy of inherent compounds in the management of skin inflammation.

Weiterlesen

]]>527Thu, 12 Mar 2026 13:34:20 +0000Letter From the New Editor-in-Chief.https://www.psoriasis-news.de/articles.html/1_articles/letter-from-the-new-editor-in-chief-r526/No abstract supplied.

Weiterlesen

]]>526Thu, 12 Mar 2026 13:34:20 +0000The Impact of Tobacco Smoking on Treatment Response Among Patients With Psoriasis Undergoing Biologic Treatment: Prospective Observational Study.https://www.psoriasis-news.de/articles.html/1_articles/the-impact-of-tobacco-smoking-on-treatment-response-among-patients-with-psoriasis-undergoing-biologic-treatment-prospective-observational-study-r525/Weiterlesen

]]>525Thu, 12 Mar 2026 13:34:20 +0000Correction to "Successful Treatment With Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis".https://www.psoriasis-news.de/articles.html/1_articles/correction-to-successful-treatment-with-spesolimab-in-a-haemodialysis-patient-with-acutely-flaring-generalised-pustular-psoriasis-r524/Weiterlesen

]]>524Thu, 12 Mar 2026 13:34:20 +0000Establishing a Generalizable Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatmentshttps://www.psoriasis-news.de/articles.html/1_articles/establishing-a-generalizable-early-improvement-cutoff-in-psoriasis-area-and-severity-index-for-outcome-prediction-across-systemic-treatments-r523/Background Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real-world practice remains unclear. Objectives To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold applicable in routine clinical practice. Methods This prospective, multicenter real-world cohort study included adult patients with moderate-to-severe plaque psoriasis receiving methotrexate, phototherapy, IL-17 inhibitors, or IL-23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week-4 PASI improvement for achieving PASI90 at 3 months and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement. Results A total of 2,023 patients were included in the analysis. The optimal week-4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL-17 inhibitors, 62% for IL-23 inhibitors, 59% for methotrexate and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months. Conclusions Achieving PASI60 at week 4 serves as a consistent and broadly applicable early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. Incorporating this threshold into early treatment assessment may help inform individualized treatment decisions and optimize outcomes in real-world management of moderate-to-severe psoriasis.

Weiterlesen

]]>523Thu, 12 Mar 2026 13:34:20 +0000Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registry.https://www.psoriasis-news.de/articles.html/1_articles/determinants-of-quality-of-life-and-mental-health-in-kenyan-psoriasis-patients-a-cross-sectional-analysis-from-the-kenyan-psoriasis-registry-r522/Weiterlesen

]]>522Thu, 12 Mar 2026 13:34:20 +0000Α-Hederin alleviates psoriasiform skin inflammation by inhibiting NF-κB p65/CXCL2 Axis.https://www.psoriasis-news.de/articles.html/1_articles/%CE%B1-hederin-alleviates-psoriasiform-skin-inflammation-by-inhibiting-nf-%CE%BAb-p65cxcl2-axis-r521/BackgroundPsoriasis is a chronic, inflammatory and systemic skin disease. Currently, none of the treatment can effectively prevent the recurrent of psoriasis. α-Hederin is the main active ingredient of the traditional Chineses medicine Ivy, which has been proven to have anti-inflammatory effects. However, its effects on psoriasis and mechanisms of action remain unclear.

Objective

This study aimed to investigate the effects of α-Hederin on murine psoriasis and its underlying mechanisms.

Methods

This study firstly evaluated the therapeutic effects of α-Hederin on psoriasis using imiquimod-induced psoriatic mice. H&E and Ki67 immunohistochemical stainings were used to observe the pathological changes and proliferation of the skin lesions. The expression of inflammatory cytokines in skin lesions was analyzed by ELISA. Subsequently, the network pharmacology was employed to predict the molecular targets of α-Hederin in psoriasis. CXCL2 expression and neutrophil infiltration in skin lesions were evaluated via immunohistochemical staining, immunofluorescent staining and flow cytometry. Finally, the effects of α-Hederin on NF-κB p65 pathway were evaluated. The binding of α-Hederin to NF-κB p65 protein was verified through molecular docking, molecular dynamics simulation, CETSA and DARTS.

Results

α-Hederin significantly improved IMQ-induced psoriasiform skin lesions and inflammation in mice. It also reduced the expression of CXCL2 and infiltration of CD11b+Ly6G+ neutrophils in the skin of psoriatic mice. Importantly, administration of recombinant CXCL2 protein aggravated the skin lesions and increased CD11b+Ly6G+ neutrophil infiltration in psoriatic mice previously treated with α-Hederin. Furthermore, α-Hederin inhibited the production of CXCL2 in HaCaT cells and migration of neutrophils to HaCaT cells. But these effects were completely reversed by the CU-T12-9, an NF-κB p65 agonist. Similarly, α-Hederin failed to further alleviate psoriasiform skin lesions and inflammation in mice treated with SC75741 (NF-κB p65 inhibitor). Finally, based on molecular docking, molecular dynamics simulation, CETSA and DARTS, NF-κB p65 was revealed as the direct target of α-Hederin in treating psoriasis.

Conclusion

This study has provided the first evidence that α-Hederin may be a promising anti-psoriatic drug by inhibiting NF-κB p65/CXCL2 axis.

Weiterlesen

]]>521Wed, 11 Mar 2026 16:16:46 +0000Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.https://www.psoriasis-news.de/articles.html/1_articles/nanocarriers-smart-biomaterials-and-emerging-therapeutics-for-psoriasis-current-progress-and-future-directions-r520/Weiterlesen

]]>520Wed, 11 Mar 2026 16:16:46 +0000Correction to “Successful Treatment With Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis”https://www.psoriasis-news.de/articles.html/1_articles/correction-to-successful-treatment-with-spesolimab-in-a-haemodialysis-patient-with-acutely-flaring-generalised-pustular-psoriasis-r519/No abstract supplied.

Weiterlesen

]]>519Wed, 11 Mar 2026 16:16:46 +0000Screening practice of cardiovascular risk and psoriatic arthritis among patients with psoriasis in primary care.https://www.psoriasis-news.de/articles.html/1_articles/screening-practice-of-cardiovascular-risk-and-psoriatic-arthritis-among-patients-with-psoriasis-in-primary-care-r518/BackgroundGeneral Practitioners (GPs) act as primary gatekeepers for patients with psoriasis and their screening practice for cardiovascular disease (CVD) and psoriastic arhtiris (PsA) y. This study aimed to assess the awareness and screening routines of Danish GPs regarding CVD and PsA in patients with psoriasis.

Methods

A nationwide cross-sectional survey on screening practice was conducted involving 490 randomly selected Danish GPs. Data were analyzed descriptively based on 101 responses (21% response rate).

Results

The survey revealed a high level of awareness regarding CVD risk (84%), with 60% of GPs reporting routine screening for cardiovascular issues. Commonly assessed parameters included blood pressure (93%) and cholesterol (67%). Conversely, screening for PsA was notably less frequent, with only 32% of GPs actively screening for PsA.

Conclusion

While screening and awareness of CVD risk among primary care professionals, PsA screening remains suboptimal. The findings suggest an urgent need for updated guidelines endorsing simple, validated PsA screening tools and targeted education to prevent missed opportunities for early diagnosis.

Weiterlesen

]]>518Wed, 11 Mar 2026 15:51:58 +0000Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events.https://www.psoriasis-news.de/articles.html/1_articles/choice-of-biologic-immunotherapy-for-psoriasis-or-psoriatic-arthritis-and-its-association-with-risk-of-major-adverse-cardiac-events-r517/ObjectiveIndividuals with psoriasis (PsO) or psoriatic arthritis (PsA) have an elevated risk of major adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardial infarction (MI), and cerebrovascular accident (CVA). Biologic disease-modifying antirheumatic drugs (bDMARDs) may reduce cardiovascular risk; however, whether MACE risk differs by bDMARD class for this population is unknown.

Methods

Using data from TriNetX database, we identified patients with PsO/PsA who were new bDMARD users, including tumor necrosis factor inhibitors (TNFi), interleukin (IL)-17A inhibitors (-i), IL-23i, or IL-12/23i. Time-dependent risk for MACE was calculated using weighted multinomial Cox proportional hazards regression with TNFi exposure as the referent. Additional analyses evaluated components of the primary outcome and baseline cardiovascular disease. A negative control outcome was used to assess bias.

Results

We identified 32,758 patients with PsO/PsA who were new bDMARD users. Patients had PsO/PsA for a mean of 3.5 (SD 4.5) years prior to starting a biologic, the most common being TNFi (62.9%), followed by IL-17i (15.4%), IL-23i (11%), and IL-12/23i (10.7%). In weighted multinomial Cox proportional hazards regression, the adjusted risk of MACE was similar for IL-17Ai (adjusted hazard ratio [aHR] 0.98, 95% CI 0.73-1.32), IL-23i (aHR 0.84, 95% CI 0.54-1.31), and IL-12/23i (aHR 1.08, 95% CI 0.80-1.47) as compared to TNFi. Subset analyses supported the primary analysis. Negative control outcomes suggested adequate control of bias confounding.

Conclusion

MACE risk does not significantly differ across bDMARD classes in patients with PsO/PsA. Therefore, cardiovascular risk should not guide biologic selection in this population.

Weiterlesen

]]>517Wed, 11 Mar 2026 15:51:58 +0000Clinical characteristics, effectiveness, safety, and predictors of PASI75/90 responses to IL-17 biologics in psoriasis involving special sites: a large real-world cohort study revealing treatment response heterogeneity.https://www.psoriasis-news.de/articles.html/1_articles/clinical-characteristics-effectiveness-safety-and-predictors-of-pasi7590-responses-to-il-17-biologics-in-psoriasis-involving-special-sites-a-large-real-world-cohort-study-revealing-treatment-response-heterogeneity-r516/P < 0.0001. Treatment response rates were 74.0% for PASI50, 58.6% for PASI75, and 41.5% for PASI90, while adverse events were rare (0.75%). Prediction models for PASI75 and PASI90 responses exhibited moderate discriminative ability. Independent predictors for both PASI75 and PASI90 included clinical BMI, DLQI, BSA, and IGA (all P < 0.05), while job status was an independent predictor for PASI90 only (P < 0.05).Overall, IL-17 inhibitors show substantial efficacy and a favorable safety profile for psoriasis in special sites, with treatment response variability influenced primarily by baseline clinical characteristics such as BMI and disease severity indices.

Weiterlesen

]]>516Wed, 11 Mar 2026 15:51:58 +0000Integrating network pharmacology and experimental validation to elucidate the mechanism of Xiao-bi decoction in psoriasis treatment: Inhibition of JAK2/STAT3 signaling and rebalancing Th17/Treg responses.https://www.psoriasis-news.de/articles.html/1_articles/integrating-network-pharmacology-and-experimental-validation-to-elucidate-the-mechanism-of-xiao-bi-decoction-in-psoriasis-treatment-inhibition-of-jak2stat3-signaling-and-rebalancing-th17treg-responses-r515/Ethnopharmacological relevanceThe traditional Chinese herbal medicine called Xiao-bi decoction (XBD) has been used for decades to treat psoriasis, but its mechanism of action is poorly understood.

Aim of the study

To investigate the underlying mechanism of XBD against psoriasis using systematic pharmacological techniques.

Materials and methods

A psoriasis model was established in mice using imiquimod (IMQ). The efficacy of XBD was evaluated based on psoriasis severity scores and immune cell infiltration. Core components and targets were screened using UPLC-QE-MS/MS and network pharmacology. The mechanism was further explored via transcriptome sequencing, ELISA, western blotting, immunolocalization, and molecular docking.

Results

XBD treatment significantly alleviated IMQ-induced psoriatic symptoms like erythema, scaling, and thickening. It reduced CD4+ T cell infiltration in skin and decreased serum levels of IL-17, IL-1β, IL-23, and IL-36. XBD specifically decreased CD4+-IL-17+ cells while increasing CD4+-FoxP3+ cells in both blood and skin. A total of 1223 chemical components were identified in XBD, including 78 blood-entering components. Network pharmacology and transcriptome analysis collectively demonstrate that XBD inhibits the activation of the JAK2/STAT3 signaling pathway, indicating its potential role in modulating this pathway. Our results also showed that XBD modulated Th17/Treg balance in serum and ameliorating skin inflammation in IMQ-induced psoriatic model.

Conclusion

The herbal medicine Xiao-bi decoction may regulate the JAK2/STAT3 pathway, thereby influencing the Th17 response and Treg differentiation, and thereby alleviating the skin inflammation of psoriasis.

Weiterlesen

]]>515Wed, 11 Mar 2026 15:51:58 +0000Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/baseline-clinical-and-metabolic-predictors-of-52-week-durability-of-secukinumab-response-in-moderate-to-severe-plaque-psoriasis-r514/BackgroundDurability of response to IL-17A blockade (secukinumab) varies, representing a major clinical challenge. Psoriasis is inherently linked to immunometabolic dysfunction. We hypothesized that simple, routine metabolic indices could predict long-term treatment stability, offering crucial pre-treatment stratification tools.

Methods

This was a 52-week prospective, single-center cohort study of 118 patients with moderate-to-severe plaque psoriasis initiating secukinumab. We defined Durable Response (DR) as PASI90 at Week 12 maintained as absolute PASI ≤ 2 until Week 52. Multivariable logistic regression and Cox models were used to identify independent predictors of DR and drug survival.

Results

Independent predictors of durable response were biologic-naïve status (adjusted OR = 3.52, 95% CI: 1.58-7.85) and a lower baseline TG/HDL-C ratio (adjusted OR = 0.61, 95% CI: 0.47-0.79). Conversely, obesity (BMI≥30) (OR = 0.42) and higher baseline PASI (OR = 0.91) were associated with reduced odds of DR. Conventional systemic inflammatory markers (CRP, NLR) showed no significant difference. Drug survival was significantly higher in DRs (92.6% vs 78.3% at Week 52) and was independently reduced by psoriatic arthritis.

Conclusion

The routine baseline TG/HDL-C ratio is a strong, independent predictor of sustained secukinumab efficacy. These easily accessible clinical and metabolic features capture the immunometabolic milieu influencing IL-17A inhibition durability. Integrating the TG/HDL-C ratio into pre-treatment assessment can support patient stratification and optimize long-term management strategies for plaque psoriasis.

Weiterlesen

]]>514Wed, 11 Mar 2026 15:51:58 +0000The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review.https://www.psoriasis-news.de/articles.html/1_articles/the-emerging-role-of-gut-microbiota-in-inflammatory-skin-diseases-a-systematic-review-r513/Weiterlesen

]]>513Wed, 11 Mar 2026 15:51:58 +0000PBMC transcriptomic signatures reflect immune dynamics and disease activity in psoriatic arthritishttps://www.psoriasis-news.de/articles.html/1_articles/pbmc-transcriptomic-signatures-reflect-immune-dynamics-and-disease-activity-in-psoriatic-arthritis-r512/No abstract supplied.

Weiterlesen

]]>512Wed, 11 Mar 2026 15:51:58 +0000